查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1378628

肺癌诊断与筛检市场：依测试类型、癌症类型、最终用户、地区分类

Lung Cancer Diagnostic and Screening Market, By Test Type (Biomarkers Test Imaging Test (Computed Tomography scan, Positron Emission Tomography scan, Chest X-Ray, Others), Biopsy), By Cancer Type, By End User, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计到 2023 年，全球肺癌诊断和筛检市场将达到 24.587 亿美元，预测期内（2023-2030 年）年复合成长率为 10.1%。

报告范围 报告详情
基准年 2022年 2023年市场规模 24.587 亿美元
实绩资料 2018-2021 预测期 2023-2030
预测期年复合成长率 10.10% 2030年市场规模预测 48.356 亿美元
图 1. 2023 年按测试类型分類的肺癌诊断和筛检的全球市场占有率(%)
肺癌诊断及筛检市场-IMG1

肺癌是一种由肺部细胞分裂失控引起的疾病。作为其正常功能的一部分，细胞会分裂并自我复製更多。受损细胞不受控制的分裂会导致组织肿瘤，最终导致器官停止正常运作。肺癌始于肺部，通常发生于气道（细支气管或细支气管）或小气囊（肺泡）。从其他地方开始并扩散到肺部的癌症通常以它们开始的地方命名。肺癌的治疗包括手术、射频消融、放射线治疗、化疗、标靶药物治疗和免疫治疗。该行业的主要参与者专注于开发技术先进的产品。因此，将此类先进产品引入市场预计将在预测期内推动全球肺癌诊断和筛检市场的成长。

市场动态

该行业的主要参与者专注于开发用于各种外科手术的技术先进的设备、仪器和系统。因此，将此类先进产品引入市场预计将在预测期内推动全球肺癌诊断和筛检市场的成长。例如，2021年5月，分子诊断、应用测试、学术和药物研究的样本和检测技术提供者QIAGEN宣布，therascreen KRAS RGQ PCR试剂盒（therascreen KRAS Kit）将在获得美国法规机构的核准后作为为了帮助识别肺癌(NSCLC) 患者，我们宣布推出具有扩展申请的伴随诊断 (CDx)。

本研究的主要特点

  • 本报告对全球肺癌诊断和筛检市场进行了详细分析，显示了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率。
  • 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
  • 它根据公司亮点、产品系列、主要亮点、绩效和策略等参数，介绍了全球肺癌诊断和筛检市场的主要企业。
  • 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
  • 全球肺癌诊断和筛检市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 相关人员可以透过用于分析全球肺癌诊断和筛检市场的各种策略矩阵来促进他们的决策。

目录

第1章调查目的和假设

  • 这项研究的目的
  • 假设
  • 简称

第2章市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第3章市场动态、法规及趋势分析

  • 市场动态
    • 促进因素
    • 抑制因素
    • 市场机会
  • 影响分析
  • 最近测试启动
  • 流行病学
  • 合併、收购和合作
  • 法规场景
  • 主要进展
  • PEST分析

第4章全球肺癌诊断与筛检市场－新型冠状病毒感染疾病（COVID-19）影响分析

  • 经济影响
  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 对需求和供给的影响

第5章2018-2030年全球肺癌诊断与筛检市场（依检验类型）

  • 生物标记测试
  • EGFR突变检测
  • KRAS突变测试
  • ALK测试
  • HER2测试
  • 其他的
  • 影像检查
  • 电脑断层扫描 (CT) 扫描
  • 正子断层扫描 (PET) 扫描
  • 胸部X光检查
  • 其他的
  • 切片检查

第6章全球肺癌诊断与筛检市场，依癌症类型，2018-2030

  • 非小细胞肺癌
  • 小细胞肺癌

第7章全球肺癌诊断和筛检市场，按最终用户划分，2018-2030 年

  • 医院相关实验室
  • 独立诊断实验室
  • 癌症研究所
  • 其他的

第8章2018-2030年全球肺癌诊断与筛检市场（按地区）

  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中东
  • GCC
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第9章竞争形势

  • 公司简介
    • Abbott
    • Amgen Inc.,
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Lepu Medical Technology（Beijing）Co.,Ltd.
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Laboratory Corporation of America Holdings.
    • Agilent Technologies, Inc.
    • QIAGEN
    • Quest Diagnostics Incorporated.
    • NeoGenomics Laboratories.
    • Myriad Genetics, Inc.
    • GRAIL, LLC.
    • DELFI Diagnostics

第10章章

  • 参考
  • 调查方法
简介目录
Product Code: CMI4434

The global lung cancer diagnostic and screening market is estimated to be valued at US$ 2,458.7 million in 2023 and is expected to exhibit a CAGR of 10.1% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 2,458.7 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 10.10% 2030 Value Projection: US$ 4,835.6 Mn
Figure 1. Global Lung Cancer Diagnostic and Screening Market Share (%), By Test Type, 2023
Lung Cancer Diagnostic and Screening Market - IMG1

Lung cancer is a disease caused by uncontrolled cell division in lungs. Cells divide and make more copies of themselves as part of their normal function. The uncontrolled division of damaged cells results in tissue tumors, which eventually prevent organs from functioning properly. Lung cancer start in the lungs, commonly in the airways (bronchi or bronchioles) or small air sacs (alveoli). Cancers that begin in another location and spread to the lungs are typically named after the location of their origin. Lung cancer treatments include surgery, radiofrequency ablation, radiation therapy, chemotherapy, targeted drug therapy, and immunotherapy. Key players in the industry are focusing on the development of technologically advanced products. Thus, the introduction of such advanced products into the market is expected to drive the growth of the global lung cancer diagnostic and screening market over the forecast period.

Market Dynamics

The key players in the industry are focusing on the development of technologically advanced equipment, instruments, and systems for various surgical procedures. Thus, the introduction of such advanced products in the market is expected to drive growth of the global lung cancer diagnostic and screening market over the forecast period. For instance, in May 2021, QIAGEN, a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment.

Key features of the study:

  • This report provides an in-depth analysis of the global lung cancer diagnostic and screening market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global lung cancer diagnostic and screening market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Abbott, Amgen Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Lepu Medical Technology(Beijing)Co.,Ltd., AstraZeneca, F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings., Agilent Technologies, Inc., QIAGEN, Quest Diagnostics Incorporated., NeoGenomics Laboratories., Myriad Genetics, Inc., GRAIL, LLC., DELFI Diagnostics.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global lung cancer diagnostic and screening market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lung cancer diagnostic and screening market.

Global Lung Cancer Diagnostic and Screening Market Detailed Segmentation:

  • By Test Type:
    • Biomarkers Test
    • EGFR Mutation Test
    • KRAS Mutation Test
    • ALK Test
    • HER2 Test
    • Others
    • Imaging Test
    • Computed Tomography (CT) scan
    • Positron Emission Tomography (PET) scan
    • Chest X-Ray
    • Others
    • Biopsy
  • By Cancer Type:
    • Non-small cell lung cancer
    • Small Cell Lung Cancer
  • By End User:
    • Hospital Associated Labs
    • Independent Diagnostic Laboratories
    • Cancer Research Institutes
    • Others
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles
    • Abbott
    • Amgen Inc.,
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Lepu Medical Technology(Beijing)Co.,Ltd.
    • AstraZeneca
    • F.Hoffmann-La Roche Ltd
    • Laboratory Corporation of America Holdings.
    • Agilent Technologies, Inc.
    • QIAGEN
    • Quest Diagnostics Incorporated.
    • NeoGenomics Laboratories.
    • Myriad Genetics, Inc.
    • GRAIL, LLC.
    • DELFI Diagnostics.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Test Type
    • Market Snippet, By Cancer Type
    • Market Snippet, By End User
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Test Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global Lung Cancer Diagnostic and Screening Market - COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Lung Cancer Diagnostic and Screening Market, By Test Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Biomarkers Test
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • EGFR Mutation Test
  • KRAS Mutation Test
  • ALK Test
  • HER2 Test
  • Others
  • Imaging Test
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Computed Tomography (CT) scan
  • Positron Emission Tomography (PET) scan
  • Chest X-Ray
  • Others
  • Biopsy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

6. Global Lung Cancer Diagnostic and Screening Market, By Cancer Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Non-small cell lung cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Small Cell Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

7. Global Lung Cancer Diagnostic and Screening Market, By End User, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Associated Labs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Independent Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Cancer Research Institutes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Lung Cancer Diagnostic and Screening Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Test Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Test Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Test Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Test Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Test Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Test Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profiles
    • Abbott
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Amgen Inc.,
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Lepu Medical Technology(Beijing)Co.,Ltd.
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Laboratory Corporation of America Holdings.
    • Agilent Technologies, Inc.
    • QIAGEN
    • Quest Diagnostics Incorporated.
    • NeoGenomics Laboratories.
    • Myriad Genetics, Inc.
    • GRAIL, LLC.
    • DELFI Diagnostics

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact